268 related articles for article (PubMed ID: 32810272)
1. Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy.
Zhuang J; Tan J; Wu C; Zhang J; Liu T; Fan C; Li J; Zhang Y
Nucleic Acids Res; 2020 Sep; 48(16):8870-8882. PubMed ID: 32810272
[TBL] [Abstract][Full Text] [Related]
2. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.
Yao X; Lyu P; Yoo K; Yadav MK; Singh R; Atala A; Lu B
J Extracell Vesicles; 2021 Mar; 10(5):e12076. PubMed ID: 33747370
[TBL] [Abstract][Full Text] [Related]
3. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.
Xu Q; Zhang Z; Zhao L; Qin Y; Cai H; Geng Z; Zhu X; Zhang W; Zhang Y; Tan J; Wang J; Zhou J
J Control Release; 2020 Oct; 326():455-467. PubMed ID: 32711027
[TBL] [Abstract][Full Text] [Related]
4. Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib.
He C; Jaffar Ali D; Xu H; Kumaravel S; Si K; Li Y; Sun B; Ma J; Xiao Z
Exp Cell Res; 2020 Jul; 392(2):112040. PubMed ID: 32380039
[TBL] [Abstract][Full Text] [Related]
5. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
Whitley JA; Cai H
J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
[TBL] [Abstract][Full Text] [Related]
6. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 Genome Editing vs. Over-Expression for Fluorescent Extracellular Vesicle-Labeling: A Quantitative Analysis.
Strohmeier K; Hofmann M; Hauser F; Sivun D; Puthukodan S; Karner A; Sandner G; Le Renard PE; Jacak J; Mairhofer M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008709
[TBL] [Abstract][Full Text] [Related]
8. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
Xiao S; Liu Z; Deng R; Li C; Fu S; Chen G; Zhang X; Ke F; Ke S; Yu X; Wang S; Zhong Z
J Control Release; 2017 Jul; 258():130-145. PubMed ID: 28522194
[TBL] [Abstract][Full Text] [Related]
10. Encapsulating Cas9 into extracellular vesicles by protein myristoylation.
Whitley JA; Kim S; Lou L; Ye C; Alsaidan OA; Sulejmani E; Cai J; Desrochers EG; Beharry Z; Rickman CB; Klingeborn M; Liu Y; Xie ZR; Cai H
J Extracell Vesicles; 2022 Apr; 11(4):e12196. PubMed ID: 35384352
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
12. Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.
O'Brien KP; Khan S; Gilligan KE; Zafar H; Lalor P; Glynn C; O'Flatharta C; Ingoldsby H; Dockery P; De Bhulbh A; Schweber JR; St John K; Leahy M; Murphy JM; Gallagher WM; O'Brien T; Kerin MJ; Dwyer RM
Oncogene; 2018 Apr; 37(16):2137-2149. PubMed ID: 29367765
[TBL] [Abstract][Full Text] [Related]
13. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
14. Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation.
Lainšček D; Kadunc L; Keber MM; Bratkovič IH; Romih R; Jerala R
ACS Synth Biol; 2018 Dec; 7(12):2715-2725. PubMed ID: 30513193
[TBL] [Abstract][Full Text] [Related]
15. Surface Engineering of HEK293 Cell-Derived Extracellular Vesicles for Improved Pharmacokinetic Profile and Targeted Delivery of IL-12 for the Treatment of Hepatocellular Carcinoma.
Zhang J; Song H; Dong Y; Li G; Li J; Cai Q; Yuan S; Wang Y; Song H
Int J Nanomedicine; 2023; 18():209-223. PubMed ID: 36660339
[TBL] [Abstract][Full Text] [Related]
16. Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing.
Rouet R; Thuma BA; Roy MD; Lintner NG; Rubitski DM; Finley JE; Wisniewska HM; Mendonsa R; Hirsh A; de Oñate L; Compte Barrón J; McLellan TJ; Bellenger J; Feng X; Varghese A; Chrunyk BA; Borzilleri K; Hesp KD; Zhou K; Ma N; Tu M; Dullea R; McClure KF; Wilson RC; Liras S; Mascitti V; Doudna JA
J Am Chem Soc; 2018 May; 140(21):6596-6603. PubMed ID: 29668265
[TBL] [Abstract][Full Text] [Related]
17. Aptamer-Modified Tetrahedral DNA Nanostructure for Tumor-Targeted Drug Delivery.
Li Q; Zhao D; Shao X; Lin S; Xie X; Liu M; Ma W; Shi S; Lin Y
ACS Appl Mater Interfaces; 2017 Oct; 9(42):36695-36701. PubMed ID: 28991436
[TBL] [Abstract][Full Text] [Related]
18.
Ye Y; Shi Q; Yang T; Xie F; Zhang X; Xu B; Fang J; Chen J; Zhang Y; Li J
Technol Cancer Res Treat; 2022; 21():15330338221085370. PubMed ID: 35315725
[No Abstract] [Full Text] [Related]
19. A Self-Assembled Platform Based on Branched DNA for sgRNA/Cas9/Antisense Delivery.
Liu J; Wu T; Lu X; Wu X; Liu S; Zhao S; Xu X; Ding B
J Am Chem Soc; 2019 Dec; 141(48):19032-19037. PubMed ID: 31729871
[TBL] [Abstract][Full Text] [Related]
20. A novel dual-targeting delivery system for specific delivery of CRISPR/Cas9 using hyaluronic acid, chitosan and AS1411.
Khademi Z; Ramezani M; Alibolandi M; Zirak MR; Salmasi Z; Abnous K; Taghdisi SM
Carbohydr Polym; 2022 Sep; 292():119691. PubMed ID: 35725215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
